Therapeutic options for hormone-refractory prostate cancer

被引：0
作者：
Miller K. [1 ,6 ]
Börgermann C. [2 ]
Thüroff J. [3 ]
Albers P. [4 ]
Wirth M. [5 ]
机构：
[1] Urologische Klinik, Charité, Universitätsmedizin, Berlin
[2] Klinik und Poliklinik für Urologie, Universitätsklinikum, Essen
[3] Urologische Klinik, Johannes-Gutenberg-Universität, Mainz
[4] Urologische Klinik, Universität, Bonn
[5] Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Technische Universität, Dresden
[6] Urologische Klinik, Charité, Universitätsmedizin, 12200 Berlin
来源：
Der Urologe | 2006年 / 45卷 / 5期
关键词：
Docetaxel; Hormone-refractory prostate cancer; Taxanes; Zoledronic acid;
D O I：
10.1007/s00120-006-1048-0
中图分类号：
学科分类号：
摘要：
For a long time, hormone-refractory prostate cancer was regarded as a chemoresistant tumor. The introduction of taxanes has prompted a change in this opinion. For the first time treatment with 75 mg/m 2 docetaxel every 3 weeks has evidenced a survival benefit in a phase III trial (median survival of 18.9 months versus 16.5 months with mitoxantrone). Further advantages were improved pain reduction and quality of life. Neutropenia was foremost among the side effects. Docetaxel is currently the standard treatment for hormone-refractory prostate cancer. The morbidity of metastatic hormone-refractory prostate cancer is influenced by bone metastases. Pain is a prominent feature. Skeletal complications are frequent. Therapy with 4 mg zoledronic acid reduced skeletal complications significantly in comparison to placebo. The most pronounced effect is the reduction of pathological fractures. Side effects include flu-like symptoms, muscle pain, and edemas. Zoledronic acid also belongs to the standard treatment of hormone-refractory prostate cancer with bone metastases. © Springer Medizin Verlag 2006.
引用
收藏
页码：580 / 585
页数：5
相关论文
共 21 条
  • [1] Aus G., Abbou C.C., Bolla M., Et al., EAU guidelines on prostate cancer, Eur Urol, 48, pp. 546-551, (2005)
  • [2] Bamias A., Kastritis E., Bamia C., Et al., Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors, J Clin Oncol, 23, pp. 8580-8597, (2005)
  • [3] Berruti A., Dogliotti L., Tucci M., Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates, J Urol, 166, pp. 2023-2031, (2001)
  • [4] Eisenberger M.A., Simon R., O'Dwyer P.J., Et al., J Clin Oncol, 3, pp. 827-841, (1985)
  • [5] Fox E.J., Mechanism of action of mitoxantrone, Neurology, 63, pp. 15-18, (2004)
  • [6] Haldar S., Basu A., Croce C.M., Bcl2 is the guardian of microtubule integrity, Cancer Res, 57, pp. 229-233, (1997)
  • [7] Kantoff P.W., Halabi S., Conaway M., Et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study, J Clin Oncol, 17, pp. 2506-2513, (1999)
  • [8] Marx R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J Oral Maxillofac Surg, 61, pp. 1115-1117, (2003)
  • [9] Miller K., Wulfing C., Lehmann J., Et al., Weekly docetaxel plus estramustine for hormone-refractory prostate cancer (HRPC) with intermittent repetition: Preliminary results of a multicenter Phase II study (AUO AP33/02), J Clin Oncol, 23, (2005)
  • [10] Oh W.K., Manola J., Babcic V., Et al., Response to second-line chemotherapy in patients with hormone refractory prostate cancer (HRPC) receiving two sequences of mitoxantrone (M) and taxanes (T), J Clin Oncol, 23, (2005)
123